FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
As of 11:25 UTC on 20 Oct 2026, Kalshi prices “FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)” at 92%. The market has no Kalshi-reported volume in the last 24 hours. pdata.world compares it with 24 related events on Kalshi, Polymarket and Manifold.
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in. It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma. In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.
